PRESS RELEASE ON MEXICO'S
2ND ANNUAL POST POLIO SYNDROME SYMPOSIUM
Liliana Marasco Garrido, President and Co-Founder of Litaff
Shari Fiksdal, President & Co-Founder of International
Post Polio Support
THE LATEST NEWS ON POST POLIO SYNDROME (PPS)
Three important issues came from the symposium, we feel it is important that we share this latest news with everyone.
Some may already know there is a WHO Code for Post Polio Syndrome, that there is
a possible marker waiting for approval by the ...Journal
And that they are continuing to find IV Gamma globulin is helping those
of us with PPS! We apologize that this release has been delayed due to to ill health.
LATEST INVESTIGATIONS INTO THE CAUSE OF POST POLIO SYNDROME
Dr. Brian Joseph, PhD. (Harvard) brought us up to date on IV Gamma Globulin Studies of
Dr. H. Gonzalez! Dr. Kristian Borg and Henrick Gonzalez in Sweden have been working for
many years testing the benefits of IV Gamma Globulin for PPS patients.
Dr. Joseph asked Dr. Henrik Gonzalez about their test results since their last release in 2008.
Dr. Joseph explained that the tests being done in Sweden by
Dr. Henrick Gonzalez and Dr. Kristian Borg had proven to be successful
and their research into the cause of PPS was “revolutionary
1. The study proved gamma helps PPS.
2. The study shows we have fragments of polio protein in our spinal cords, which causes our immune systems to continue to battle the polio virus that was there. This and not dying neurons is what is causing PPS by weakening our immune systems. Our body is still in the fight mode to kill off the tiny polio fragments in our bodies. This does not mean we still have polio, just remnants of the old virus our immune systems are still attacking, causing further degeneration.
3. And even more importantly, they have found a blood test to tell if you have PPS!
Dr. Brian Joseph
The details will all be released as soon as the peer review process is complete.
From: Henrik Gonzalez
Date: 5 de agosto de 2010 14:34:29 CDT
To: "Asociacion Postpolio Litaff A.C_ APPLAC" <email@example.com>
RE: Re: Dr. Henrik Gonzales Regards From México PPS Organization
Very nice to hear from You Liliana.
Brian and I have corresponded for some years. For your information, we have two unpublished studies.
When studies are unpublished I am not able to tell you too much about the results, but:
The first is the one year follow up of Xepol (IVIG) with very promising results and the other
a method to diagnose PPS by a very simple blood test.
Very warm regards
You can read below that Grifols has already bought the rights to Xepol:
Mtra. RitaVelásquez Lerma,
Subdirectora de Registros de Salud y Discapacidad Del INEGI
World Health Code for PPS “G 14” for PPS:
In 2009 and as a result of the annual meeting of the Committee on
Review and Update of the World Health Organization (WHO), which
took place in the Indian capital Delhi during the month of October 2008,
the International Classification Diseases, version 10 (ICD-10) has been awarded
a specific location to Post-Polio Syndrome (PPS) classified under
the code "G14" and excluded from code B91 (Sequelae of poliomyelitis), which
considered it before this body covered. International Statistical Classification of
Diseases and Related Health Problems. "With these changes the codes are assigned by
the WHO as one can read:"
Classification of polio sequelae and late effects and secondary
(ICD-10, WHO) .
Transfer Factor and IV Gamma studies in Mexico!
Dra. Rodriguez is already using Transfer Factor in Mexico and had just finished
her studies with PPS and IV gamma.
Dra. Rodriguez said she had found gamma to be helpful in other
Central Nervous System illnesses
and was looking forward to furthering her studies with PPS.
She had one medical institution and Dr. Carlos Vallbona volunteer to help her work with these studies.
Warm regards to all,
Mrs. Liliana Marasco Garrido Shari Fiksdal, President & Co-Founder
Post Polio Association Litaff ,A.C_APPLAC International Post Polio Support Org.
Mr. Ernesto Maury Ruiz
Vice President & Cofounder
STOCKHOLM, SWEDEN – 26 August, 2008 ‐
Pharmalink AB today announces positive results from a follow‐on Phase III study of Xepol®,
Xepol®, the first medical PPS treatment , is an injectable biologic product, administered once per 9‐12 months, which down